Page 3 - Mike Sinclair News Today

Series C led by Pureos BioventuresFinancing to support completion of a Phase II trial of AntiBKV and to prepare manufacturing of drug for Phase IIISCHLIEREN / ZURICH, Switzerland--(BUSINESS WIRE)--Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced to...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 6, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares (the “ADS Ratio”) from the current ADS Ratio of one (1) ADS to six (6) ordinary shares to a new ADS Ratio of one (1) ADS...

Aberdein Considine has strengthened its residential property team with the appointment of Ashleigh Urwin as a partner. Ms Urwin brings over 10 years’ experience in residential property and will be based at the firm’s Elm Row office in Edinburgh.

Geneva, Switzerland, September 6, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...

Cohort 1 is completed, and Cohort 2 is 80% recruited Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 5, 2023 - Addex Therapeutics , a clinical-stage pharmaceutical company...

Cohort 1 is completed, and Cohort 2 is 80% recruited Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 5, 2023 - Addex...

Landmark study shows mGlu5 receptor negative allosteric modulators (NAMs) restore lost neurological functionsFirst time mGlu5 linked to post-strok...

Geneva, Switzerland, August 3, 2023 – Addex Therapeutics , a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will...

Data published in Neuropharmacology shows mGlu2 PAMs attenuate oxycodone use and potential as a novel treatment for opioid use disorder Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 24, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced data showing that administration of a metabotropic glutamate 2 (mGlu2) positive allosteric modulator significantly

Discover the latest Architecture news and projects on Kansas City at ArchDaily, the world's largest architecture website. Stay up-to-date with articles and updates on the newest developments in architecture.